Ranbaxy

I'll research this company before writing the profile.

Ranbaxy Laboratories Limited ("Ranbaxy") is an Indian generic pharmaceutical manufacturer founded in 1961, with roots going back to a 1937 drug-distribution business. It was headquartered in Gurgaon, Haryana, India, and for decades was among India's largest drugmakers, listed on the BSE, NSE and Luxembourg exchanges. Japan's Daiichi Sankyo acquired a controlling stake in 2008; Sun Pharmaceutical Industries Ltd. (NSE/BSE: SUNPHARMA) acquired Ranbaxy in a 2014 all-share deal completed in 2015, after which Ranbaxy was delisted and folded into Sun. Ranbaxy Inc. continues to operate as a U.S. subsidiary of Sun Pharma. Public disclosures put peak headcount at roughly 14,600 (2012 annual report); FY2013–14 net sales were about Rs 10,614 crore. Current standalone revenue or headcount figures for the Ranbaxy brand are not separately reported.

Products/operations: Ranbaxy developed and manufactured generic prescription formulations, branded generics, over-the-counter consumer brands (including Volini and Revital), and active pharmaceutical ingredients and intermediates, with therapeutic focus on anti-infectives, cardiovascular, CNS, dermatology, urology, metabolic and respiratory areas. Its products were sold in more than 125 countries. Its U.S. history includes FDA import alerts at Indian plants, a 2013 guilty plea and $500 million U.S. Department of Justice settlement, and a consent decree.

Litigation posture: Ranbaxy is an operating company, not an NPE. In the tracked data it appears only as a defendant (0 plaintiff, 1 defendant), consistent with a drugmaker defending competition claims rather than asserting patents. Its tracked matter sits in the Northern District of California, not a plaintiff-friendly patent venue.

Notable case: In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal., MDL No. 20-md-02966-RS), where Ranbaxy was named among generic-manufacturer defendants alleged to have settled patent litigation with Jazz Pharmaceuticals; Jazz's May 2016 settlement granted Ranbaxy a license to market generic sodium oxybate on or after December 31, 2025. Related non-tracked Ranbaxy antitrust matters include the D. Mass. MDL No. 2878 (In re Ranbaxy Generic Drug Application Antitrust Litigation), settled for $485 million in 2022, and atorvastatin/Lipitor pay-for-delay claims.